Aravive logo
Aravive ARAV

Quarterly report 2023-Q3
added 11-09-2023

report update icon

Aravive Financial Statements 2011-2026 | ARAV

Annual Financial Statements Aravive

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

60.4 M 44.2 M 84.3 M 118 M 27.2 M 72.2 M 400 M 323 M 335 M 366 K 297 K 1.82 M

Shares

36.4 M 20.1 M 16.1 M 11.6 M 7.17 M 5.87 M 5.13 M 4.83 M 3.15 M 141 K 141 K 3.88 M

Historical Prices

1.66 2.2 6.81 8.54 5.83 9.6 131 39.4 119 - - -

Net Income

-76.3 M -39.2 M -30.5 M -18.2 M -76.3 M -85 M -95.8 M -82.2 M -57.5 M -18.5 M -13.2 M -7.17 M

Revenue

9.14 M 7.44 M 5.68 M 4.75 M 1.37 M 40 M - - - - - -

Gross Profit

- - 5.68 K - - - - - - - - -

Operating Income

-70.8 M -40.6 M -30.8 M -21.8 M -75.4 M -84.5 M -96.3 M -82.5 M -46.1 M -19.3 M -12.9 M -

Interest Expense

2.84 M 1.46 M -14 K 2.53 M 2.43 M 528 K 236 K 113 K -11.5 M 128 K 393 K -

EBITDA

-70 M -39.7 M -23.2 M -21.3 M -36 M -84.2 M -96.1 M -82.3 M -46 M -19.3 M -12.9 M -8.14 M

Operating Expenses

80 M 48.1 M 30.7 M 26.5 M 38.5 M 124 M 96.3 M 82.5 M 46.1 M 19.3 M 12.9 M 8.16 M

General and Administrative Expenses

13 M 10.6 M 13.1 M 13.7 M 27.4 M 29.9 M 24.3 M 22.5 M 13.5 M 4.43 M 1.94 M 1.78 M

All numbers in USD currency

Quarterly Income Statement Aravive

2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

75.7 M 75.7 M 75.7 M 59.8 M 30.5 M 30.5 M 21.1 M 21 M 20.8 M 20.4 M 18.1 M 16.5 M 16.1 M 15.9 M 15 M 15 M 11.3 M 11.3 M 11.3 M 11.3 M 6.04 M 6.02 M 6 M 35.9 M 35.7 M 35.3 M 35 M 34.6 M 29.6 M 29.5 M 29.4 M 29.4 M 29.4 M 29.3 M 27.8 M 24.2 M 24.2 M 24.2 M 2.79 M 1.26 M 251 K 148 K 133 K - - - - - - - -

Net Income

21.2 M 18 M -50 M - -15.7 M -18.5 M -13.1 M - -11.1 M -7.1 M -8 M - -10.7 M -5.04 M -10.8 M - -6.14 M -3.04 M -4.7 M - -6.55 M -9.85 M -8.98 M 31.1 M -49.8 M -36.6 M -29.7 M -22.1 M -27.3 M -22.1 M -24.2 M -20.1 M -20.4 M -19.7 M -22 M -15.7 M -13.8 M -8.6 M -19.4 M -5.81 M -5.01 M -3.66 M -4.02 M - - - - - - - -

Revenue

2.76 M 1.27 M 1.49 M - 4.96 M 1.62 M 1.09 M - 2.41 M 3.79 M 256 K - - - - - 4.75 M 3.05 M 1.7 M - - - - 40 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-8.91 M -12.6 M -17.9 M - -16.5 M -19.4 M -15 M - -11.6 M -7.41 M -8.01 M - -10.7 M -5.72 M -10.3 M - -7 M -3.87 M -5.74 M - -6.22 M -9.44 M -8.52 M 31.1 M -49.7 M -36.2 M -29.7 M -22.5 M -27.4 M -22.3 M -24.1 M -20.2 M -20.5 M -19.5 M -22.3 M -15.9 M -14.1 M -8.5 M -7.58 M -5.86 M -5.26 M -3.98 M -4.18 M - - - - - - - -

Interest Expense

700 K 650 K 697 K - 738 K 705 K 703 K - 479 K 295 K -5 K - 31 K 656 K -701 K - 624 K 597 K 689 K - -593 K -656 K -657 K -547 K -262 K -521 K -261 K 446 K -39 K 59 K -230 K 32 K 91 K -236 K 226 K 244 K 208 K -141 K -11.8 M 44 K 128 K 128 K 128 K - - - - - - - -

EBITDA

- - -17.7 M - -15.9 M -19 M -14.8 M - -10.8 M -6.92 M -7.77 M - -9.1 M -4.57 M -10.2 M - -6.62 M -3.63 M -5.61 M - -5.24 M -9.2 M -8.4 M 31.1 M -49.6 M -36.1 M -29.6 M -22.5 M -27.3 M -22.2 M -24.1 M -20.2 M -20.4 M -19.4 M -22.2 M -15.9 M -14 M -8.48 M -7.58 M -5.86 M -5.25 M -3.97 M -4.18 M - - - - - - - -

Operating Expenses

11.7 M 13.9 M 19.4 M - 21.5 M 21 M 16.1 M - 14 M 11.2 M 8.26 M - 10.7 M 5.72 M 10.3 M - 7 M 6.93 M 7.44 M - 6.22 M 9.44 M 8.52 M 8.89 M 49.7 M 36.2 M 29.7 M 22.5 M 27.4 M 22.3 M 24.1 M 20.2 M 20.5 M 19.5 M 22.3 M 15.9 M 14.1 M 8.5 M 7.58 M 5.86 M 5.26 M 3.98 M 4.18 M - - - - - - - -

General and Administrative Expenses

2.94 M 3.07 M 3.49 M - 2.84 M 3.73 M 3.09 M - 2.64 M 3.08 M 2.38 M - 2.72 M 3.2 M 3.95 M - 3.16 M 3.29 M 4.59 M - 5.19 M 6 M 4.92 M 7.57 M 7.07 M 7.57 M 7.66 M 5.76 M 6.75 M 5.91 M 5.92 M 4.62 M 5.12 M 7.56 M 5.18 M 4.34 M 3.58 M 2.88 M 2.71 M 2.4 M 685 K 656 K 682 K - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Aravive ARAV
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Aravive plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.68 2.44 % $ 429 M britainBritain
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Kamada Ltd. Kamada Ltd.
KMDA
$ 8.81 1.73 % $ 260 M israelIsrael
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Adagene Adagene
ADAG
$ 3.26 0.62 % $ 183 M chinaChina
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.28 -2.62 % $ 7.89 B australiaAustralia
Evogene Ltd. Evogene Ltd.
EVGN
$ 0.81 -9.28 % $ 27.9 M israelIsrael
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Nymox Pharmaceutical Corporation Nymox Pharmaceutical Corporation
NYMX
- -19.68 % $ 18.4 M canadaCanada
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.79 -1.29 % $ 4.31 M chinaChina
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
XTL Biopharmaceuticals Ltd. XTL Biopharmaceuticals Ltd.
XTLB
$ 0.88 -1.43 % $ 442 M israelIsrael
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 224.42 -2.52 % $ 5 B danmarkDanmark
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Anavex Life Sciences Corp. Anavex Life Sciences Corp.
AVXL
$ 4.13 0.12 % $ 352 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.36 2.27 % $ 14.8 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
- 17.91 % $ 11.1 M usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Codexis Codexis
CDXS
$ 1.17 -0.85 % $ 85.9 M usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 110.12 -0.28 % $ 27.2 B germanyGermany
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 14.49 -0.75 % $ 4.48 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany